Fasting levels of the gut peptide oxyntomodulin were significantly elevated in obese adults and correlated with visceral fat and insulin resistance, suggesting it could serve as a metabolic risk biomarker.
p < 0.0001The statistical significance of elevated fasting oxyntomodulin levels in obese individuals compared to overweight and healthy-weight controls — a strong signal from a moderate-sized study.
What the researchers found
Fasting oxyntomodulin (OXM) levels were significantly higher in obese individuals compared to overweight and healthy controls (p < 0.0001). OXM levels positively correlated with visceral fat mass and volume in the obese group.
Logistic regression showed that higher OXM was significantly associated with increased risk of obesity and insulin resistance, particularly in more advanced stages of weight gain. The findings suggest OXM could serve as a measurable indicator of visceral adiposity and early metabolic dysfunction.
Why it matters
Oxyntomodulin is getting a lot of attention as a drug target — synthetic versions are being developed for weight loss. But this study flips the script and asks: what does your body's own oxyntomodulin tell us about metabolic health? The answer is that higher fasting levels of this gut peptide may flag visceral fat accumulation and insulin resistance before more serious complications develop. If validated, OXM could become a simple blood test to identify people at highest metabolic risk.
The numbers in context
n=261 total (88 overweight, 134 obese, 39 healthy controls) · OXM significantly elevated in obese vs overweight and controls (p < 0.0001) · positive correlation with visceral adipose tissue mass and volume · higher OXM associated with increased insulin resistance risk
How the study worked
A cross-sectional study comparing fasting oxyntomodulin levels across three groups: overweight adults (n=88), obese adults (n=134), and healthy controls (n=39). Body composition was measured using DXA scans and bioelectrical impedance. Researchers analyzed blood markers of glucose-insulin balance and lipid profiles, then used statistical modeling to assess whether OXM levels predicted obesity and insulin resistance.
Who was studied
261 adults: 88 overweight, 134 obese, and 39 healthy-weight controls
What this study cannot tell us
Cross-sectional design means it captures a single snapshot — it can't prove whether high OXM causes metabolic problems or results from them. The sample size of 261 is moderate. Only fasting OXM was measured, so the post-meal response wasn't captured. The study is preliminary and needs validation in larger, diverse populations.
How to read the evidence
Moderate evidence: a well-designed cross-sectional human study with validated body composition measurements and appropriate statistical analysis. However, the cross-sectional design limits causal conclusions, and the sample size, while adequate, is preliminary.
When this study was published
Published in 2025, this is a current study reflecting the latest interest in gut peptide biomarkers for metabolic disease stratification.
The bigger picture
While pharma companies race to develop synthetic oxyntomodulin analogs as weight-loss drugs, this study highlights a different angle: using the body's own OXM levels as a diagnostic tool. Current metabolic risk assessment relies on BMI, waist circumference, and fasting glucose — all imperfect. A peptide biomarker that directly reflects visceral fat accumulation and insulin resistance could improve how doctors identify and monitor at-risk patients.
Questions still open
- Do oxyntomodulin levels change in response to weight loss, and could they track treatment progress?
- Is the elevated OXM in obesity a compensatory response (the body trying to curb appetite) or a sign of OXM resistance similar to leptin resistance?
- Could combining OXM with other gut peptide biomarkers create a more accurate metabolic risk panel?
Common questions
What is oxyntomodulin and why is it relevant to obesity?
Could a blood test for oxyntomodulin replace BMI for assessing obesity risk?
Read the original research
Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity.
Journal of translational medicine, 23(1), 1400
Citation
Zwierz, Mateusz; Buczyńska, Angelika; Kościuszko, Maria; Sobieska, Katarzyna; Adamska, Agnieszka; Siewko, Katarzyna; Krętowski, Adam Jacek; Popławska-Kita, Anna. (2025). Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity.. Journal of translational medicine, 23(1), 1400. https://doi.org/10.1186/s12967-025-07479-y